SCHEMBL5207488

SCHEMBL5207488

CCOP(=O)(Cc1ccc(NC(=O)CCc2sc(NC(=O)NC)nc2-c2ccc(Cl)cc2)cc1)OCC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
MEN1 O00255 5/20 0.40
KMT2A Q03164 5/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
PTGDR2 Q9Y5Y4 7/20 0.39
GAA P10253 5/20 0.39
ALDH1A1 P00352 5/20 0.39
HTT P42858 2/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
LMNA P02545 2/20 0.39
GLA P06280 1/20 0.39
MAPK1 P28482 1/20 0.39
AGER Q15109 1/20 0.39
PLTP P55058 1/20 0.38
KDM4E B2RXH2 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
CASP3 P42574 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5210754 0.92 MAPT (0.44) MAPTMEN1KMT2ASMN1; SMN2PTGDR2
SCHEMBL6611692 0.91 MAPT (0.38) MAPTMEN1KMT2ASMN1; SMN2PTGDR2
SCHEMBL6608445 0.89 PLTP (0.47) MAPTMEN1KMT2ASMN1; SMN2PTGDR2
SCHEMBL5212864 0.89 PTGDR2 (0.43) MAPTMEN1KMT2ASMN1; SMN2PTGDR2
SCHEMBL5212166 0.89 PTGDR2 (0.54) MAPTMEN1KMT2ASMN1; SMN2PTGDR2
SCHEMBL5214026 0.89 ALDH1A1 (0.41) MAPTMEN1KMT2ASMN1; SMN2PTGDR2
SCHEMBL6609290 0.88 GRM4 (0.44) MAPTMEN1KMT2ASMN1; SMN2PTGDR2
SCHEMBL5207669 0.86 HTT (0.48) MAPTMEN1KMT2ASMN1; SMN2GAA
SCHEMBL5212184 0.85 MAPT (0.59) MAPTMEN1KMT2ASMN1; SMN2PTGDR2
SCHEMBL5210337 0.85 PTGDR2 (0.42) MAPTMEN1KMT2ASMN1; SMN2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7183276-B2 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-27 US disclosed
US-20050090534-A1 Azole compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-28 US disclosed
EP-1486490-A1 AZOLE COMPOUNDS Takeda Chemical Industries, Ltd. (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050090534-A1 Azole compounds AHR, NR0B2, NR2C2 MAPT 3958/4885MEN1 1626/4885KMT2A 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.